Boryung Pharm (003850) - Total Liabilities

Latest as of September 2025: ₩537.67 Billion KRW ≈ $364.37 Million USD

Based on the latest financial reports, Boryung Pharm (003850) has total liabilities worth ₩537.67 Billion KRW (≈ $364.37 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Boryung Pharm - Total Liabilities Trend (2009–2024)

This chart illustrates how Boryung Pharm's total liabilities have evolved over time, based on quarterly financial data. See 003850 working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Boryung Pharm Competitors by Total Liabilities

The table below lists competitors of Boryung Pharm ranked by their total liabilities.

Company	Country	Total Liabilities
ARTRYA Ltd AU:AYA	Australia	AU$2.84 Million
Ningbo Zhongbai Co Ltd SHG:600857	China	CN¥64.61 Million
SPAR Group Ltd JSE:SPP	South Africa	ZAC40.91 Billion
TINC Comm VA BR:TINC	Belgium	€35.74 Million
Jee Technology Co. Ltd. A SHG:688162	China	CN¥5.74 Billion
Mesa Laboratories Inc NASDAQ:MLAB	USA	$248.16 Million
Universal Health Realty Income Trust NYSE:UHT	USA	$415.96 Million
Martinrea International Inc. TO:MRE	Canada	CA$2.34 Billion

Liability Composition Analysis (2009–2024)

This chart breaks down Boryung Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 003850 stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.39	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.66	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.40	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Boryung Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Boryung Pharm (2009–2024)

The table below shows the annual total liabilities of Boryung Pharm from 2009 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩379.58 Billion ≈ $257.24 Million	+3.64%
2023-12-31	₩366.26 Billion ≈ $248.21 Million	-2.58%
2022-12-31	₩375.97 Billion ≈ $254.79 Million	+6.11%
2021-12-31	₩354.33 Billion ≈ $240.12 Million	+15.15%
2020-12-31	₩307.71 Billion ≈ $208.53 Million	+36.96%
2019-12-31	₩224.68 Billion ≈ $152.26 Million	+15.86%
2018-12-31	₩193.91 Billion ≈ $131.41 Million	+26.86%
2017-12-31	₩152.86 Billion ≈ $103.59 Million	-24.53%
2016-12-31	₩202.55 Billion ≈ $137.27 Million	+59.22%
2012-12-31	₩127.21 Billion ≈ $86.21 Million	+2.25%
2011-12-31	₩124.42 Billion ≈ $84.32 Million	+13.68%
2010-12-31	₩109.45 Billion ≈ $74.17 Million	+107.40%
2009-12-31	₩52.77 Billion ≈ $35.76 Million	--

About Boryung Pharm

KO:003850 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$525.57 Million

₩775.53 Billion KRW

Market Cap Rank

#12107 Global

#350 in Korea

Share Price

₩9180.00

Change (1 day)

-3.67%

52-Week Range

₩7920.00 - ₩10680.00

All Time High

₩21257.60